These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 31866327)

  • 21. Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials.
    Campbell JR; Al-Jahdali H; Bah B; Belo M; Cook VJ; Long R; Schwartzman K; Trajman A; Menzies D
    Clin Infect Dis; 2021 Nov; 73(9):e3545-e3554. PubMed ID: 32785709
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection.
    Sandul AL; Nwana N; Holcombe JM; Lobato MN; Marks S; Webb R; Wang SH; Stewart B; Griffin P; Hunt G; Shah N; Marco A; Patil N; Mukasa L; Moro RN; Jereb J; Mase S; Chorba T; Bamrah-Morris S; Ho CS
    Clin Infect Dis; 2017 Oct; 65(7):1085-1093. PubMed ID: 28575208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Isoniazid vs. rifampin for latent tuberculosis infection in jail inmates: toxicity and adherence.
    White MC; Tulsky JP; Lee JR; Chen L; Goldenson J; Spetz J; Kawamura LM
    J Correct Health Care; 2012 Apr; 18(2):131-42. PubMed ID: 22419641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adverse events associated with treatment of latent tuberculosis in the general population.
    Smith BM; Schwartzman K; Bartlett G; Menzies D
    CMAJ; 2011 Feb; 183(3):E173-9. PubMed ID: 21220436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating the effect of short-course rifapentine-based regimens with or without enhanced behaviour-targeted treatment support on adherence and completion of treatment for latent tuberculosis infection among adults in the UK (RID-TB: Treat): protocol for an open-label, multicentre, randomised controlled trial.
    Rangaka MX; Hamada Y; Duong T; Bern H; Calvert J; Francis M; Clarke AL; Ghanouni A; Layton C; Hack V; Owen-Powell E; Surey J; Sanders K; Booth HL; Crook A; Griffiths C; Horne R; Kunst H; Lipman M; Mandelbaum M; White PJ; Zenner D; Abubakar I
    BMJ Open; 2022 Sep; 12(9):e057717. PubMed ID: 36691120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.
    Jasmer RM; Saukkonen JJ; Blumberg HM; Daley CL; Bernardo J; Vittinghoff E; King MD; Kawamura LM; Hopewell PC;
    Ann Intern Med; 2002 Oct; 137(8):640-7. PubMed ID: 12379063
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan.
    Sun HY; Huang YW; Huang WC; Chang LY; Chan PC; Chuang YC; Ruan SY; Wang JY; Wang JT
    Tuberculosis (Edinb); 2018 Jul; 111():121-126. PubMed ID: 30029896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection.
    Pease C; Hutton B; Yazdi F; Wolfe D; Hamel C; Barbeau P; Skidmore B; Alvarez GG
    Pharmacoepidemiol Drug Saf; 2018 Jun; 27(6):557-566. PubMed ID: 29573031
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial.
    Nyang'wa BT; Berry C; Kazounis E; Motta I; Parpieva N; Tigay Z; Moodliar R; Dodd M; Solodovnikova V; Liverko I; Rajaram S; Rassool M; McHugh T; Spigelman M; Moore DA; Ritmeijer K; du Cros P; Fielding K;
    Lancet Respir Med; 2024 Feb; 12(2):117-128. PubMed ID: 37980911
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment completion for latent tuberculosis infection in Norway: a prospective cohort study.
    Schein YL; Madebo T; Andersen HE; Arnesen TM; Dyrhol-Riise AM; Tveiten H; White RA; Winje BA
    BMC Infect Dis; 2018 Nov; 18(1):587. PubMed ID: 30453946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of latent tuberculosis infection: a network meta-analysis.
    Stagg HR; Zenner D; Harris RJ; Muñoz L; Lipman MC; Abubakar I
    Ann Intern Med; 2014 Sep; 161(6):419-28. PubMed ID: 25111745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis.
    Winters N; Belknap R; Benedetti A; Borisov A; Campbell JR; Chaisson RE; Chan PC; Martinson N; Nahid P; Scott NA; Sizemore E; Sterling TR; Villarino ME; Wang JY; Menzies D
    Lancet Respir Med; 2023 Sep; 11(9):782-790. PubMed ID: 36966788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis.
    Ena J; Valls V
    Clin Infect Dis; 2005 Mar; 40(5):670-6. PubMed ID: 15714411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons.
    Sterling TR; Scott NA; Miro JM; Calvet G; La Rosa A; Infante R; Chen MP; Benator DA; Gordin F; Benson CA; Chaisson RE; Villarino ME;
    AIDS; 2016 Jun; 30(10):1607-15. PubMed ID: 27243774
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population.
    Jiménez-Fuentes MA; de Souza-Galvao ML; Mila Augé C; Solsona Peiró J; Altet-Gómez MN
    Int J Tuberc Lung Dis; 2013 Mar; 17(3):326-32. PubMed ID: 23407221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis.
    Fresard I; Bridevaux PO; Rochat T; Janssens JP
    Swiss Med Wkly; 2011; 141():w13240. PubMed ID: 21842452
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis.
    Yu YY; Tsao SM; Yang WT; Huang WC; Lin CH; Chen WW; Yang SF; Chiou HL; Huang YW
    Int J Environ Res Public Health; 2019 Dec; 17(1):. PubMed ID: 31892222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial.
    Cross GB; Sari IP; Kityo C; Lu Q; Pokharkar Y; Moorakonda RB; Thi HN; Do Q; Dalay VB; Gutierrez E; Balanag VM; Castillo RJ; Mugerwa H; Fanusi F; Kwan P; Chew KL; Paton NI;
    Lancet Infect Dis; 2023 Jul; 23(7):847-855. PubMed ID: 36966799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB.
    Aspler A; Long R; Trajman A; Dion MJ; Khan K; Schwartzman K; Menzies D
    Thorax; 2010 Jul; 65(7):582-7. PubMed ID: 20627913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
    Swindells S; Ramchandani R; Gupta A; Benson CA; Leon-Cruz J; Mwelase N; Jean Juste MA; Lama JR; Valencia J; Omoz-Oarhe A; Supparatpinyo K; Masheto G; Mohapi L; da Silva Escada RO; Mawlana S; Banda P; Severe P; Hakim J; Kanyama C; Langat D; Moran L; Andersen J; Fletcher CV; Nuermberger E; Chaisson RE;
    N Engl J Med; 2019 Mar; 380(11):1001-1011. PubMed ID: 30865794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.